FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC
Season 4, Episode 36, Mar 01, 2021, 08:01 PM
In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic NSCLC.